VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
|Articles|June 11, 2021
CGT Catapult Forms Consortium to Accelerate Manufacturing Technology Development
Author(s)BioPharm International Editors
The CGT Catapult has formed a consortium aimed at advancing the technology development and lowering costs of cell and gene therapy manufacturing.
Advertisement
The Cell and Gene Therapy Catapult (CGT Catapult) has formed a consortium of more than 20 organizations aimed at advancing the technology development and lowering costs of cell and gene therapy manufacturing.
In a June 8, 2021 press release, CGT Catapult announced the formation of the consortium, which will assess multiple process analytical technologies (PAT) that are either new or routinely used in other industries. Through collaboration and sharing of information, the consortium will act as a catalyst to accelerate the development of the necessary knowledge and understanding at reduced cost and investment risk to each organization.
“The industry needs to make a giant leap in terms of analytical capability and the dynamic use of information to control and improve processes, product, and costs,” said Matthew Durdy, CEO at CGT Catapult, in the press release. “The coming together of these leaders in the field is a very important first step towards achieving this.”
“By sharing knowledge and data, the consortium members will be able to reap potentially huge benefits that could lead to more efficient processes in this vital field,” added Nicholas Medcalf, deputy challenge director—Medicines Manufacturing for Innovate UK, in the press release. “The Cell and Gene Therapy Catapult—supported by Innovate UK—is demonstrating its fantastic convening power in harnessing these leading industry players for the greater good of UK enterprise and innovation.”
Source:
Advertisement
Related to this article
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5